# Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

> **NCT05387278** · PHASE1 · SUSPENDED · sponsor: **Vitti Labs, LLC** · enrollment: 20 (estimated)

## Conditions studied

- COVID-19 Acute Respiratory Distress Syndrome
- Respiratory Distress Syndrome

## Interventions

- **DRUG:** EV-Pure™ and WJ-Pure™
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05387278
- **Lead sponsor:** Vitti Labs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-03-20
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Sponsor request
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387278, "Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05387278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*